Futura Medical PLC
26 May 2004
Press Release 26 May 2004
Futura Medical announces positive initial results
from its Angina study
Futura Medical plc ('Futura'), the AIM-quoted pharmaceutical drug and medical
device group that develops innovative products for the sexual healthcare market,
announces positive initial results following the completion of its most recent
clinical trial on angina patients taking regular oral nitrates.
Fourteen patients with mild angina, low cardiovascular risk and moderate to
severe erectile dysfunction (ED) completed a pilot study at St Jean's Hospital
in Brussels, during which they received test doses of MED2001, Futura's rub-on
cream for treating ED.
The product was found to be safe and well tolerated with no clinically
significant changes in blood pressure.
Pending regulatory and ethical clearance, the results should enable Futura to
include a group of angina patients suffering from ED in the MED2001 Phase III
study scheduled to commence in late 2004.
It is currently estimated that between 5% and 10% of angina sufferers also
experience ED. For safety reasons, medication normally used to treat angina
prohibits this significant group of ED patients from using any of the current
oral ED treatments (e.g. ViagraTM, CialisTM and LevitraTM).
James Barder, Chief Executive of Futura, said: 'We are pleased that we will be
able to include a group of angina patients within our planned Phase III trial
later this year. Current medical research suggests that up to 3.5 million ED
patients suffer from angina within Europe alone. To have the potential to offer
an ethical ED treatment for some of these patients represents a significant
commercial opportunity.'
The results of the study are due to be published at the 11th World Congress of
the International Society for Sexual and Impotence Research in Buenos Aires in
October 2004.
For further information:
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0) 1483 845 670
mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk
Media enquiries:
Bankside
Peter Curtain / Alex Tweed Tel: +44 (0) 20 7444 4140
mailto:alexandra.tweed@bankside.com www.bankside.com
Notes to Editors:
Futura Medical plc
Futura Medical ('Futura' or 'the Company') is an AIM-listed pharmaceutical drug
and medical device group developing innovative products for sexual health. The
Company is developing a portfolio of products with the intention of licensing
their manufacture and distribution to major pharmaceutical and healthcare
groups. Several agreements have been signed.
Futura's primary focus is on Over the Counter ('OTC') products with particular
appeal to men and women who are reluctant to discuss potentially embarrassing
sexual matters with their doctors.
www.futuramedical.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange